HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Predictive factors for improvement of ascites after transjugular intrahepatic portosystemic shunt in patients with refractory ascites.

AbstractAIM:
The aim of this study was to investigate the predictive factors for the response of ascites to a transjugular intrahepatic portosystemic shunt (TIPS) and the impact of improvement of ascites on the overall prognosis of patients with cirrhosis and refractory ascites.
METHODS:
Forty-seven consecutive patients with liver cirrhosis who underwent TIPS for refractory ascites were studied retrospectively. The mean follow-up period was 615 ± 566 days.
RESULTS:
Thirty-six of the patients (77%) were responders at 4 weeks after TIPS (early responders) and 37 (79%) were responders at 8 weeks after TIPS. Of the 11 non-responders at 4 weeks, four showed an improvement of ascites at 8 weeks. Multivariate analysis showed that only the serum creatinine level before TIPS was an independent predictor of an early response. The cumulative survival rate of early responders was significantly higher than that of non-responders. The survival of patients grouped according to creatinine level was better in patients with serum creatinine of 1.9 mg/dL or less than in those with serum creatinine of more than 1.9 mg/dL.
CONCLUSION:
A low serum creatinine level in patients with refractory ascites is associated with an early response to TIPS. An early response of ascites to TIPS provides better survival. A serum creatinine level below 1.9 mg/dL is required for a good response to TIPS.
AuthorsYasuhiko Taki, Hidenori Kanazawa, Yoshiyuki Narahara, Norio Itokawa, Chisa Kondo, Takeshi Fukuda, Hirotomo Harimto, Yoko Matsushita, Hideko Kidokoro, Tamaki Katakura, Masanori Atsukawa, Yuu Kimura, Katsuhisa Nakatsuka, Choitsu Sakamoto
JournalHepatology research : the official journal of the Japan Society of Hepatology (Hepatol Res) Vol. 44 Issue 8 Pg. 871-7 (Aug 2014) ISSN: 1386-6346 [Print] Netherlands
PMID23819607 (Publication Type: Journal Article)
Copyright© 2013 The Japan Society of Hepatology.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: